As a biologics CDMO focused on developing and manufacturing recombinant protein products using mammalian cell culture ...
Nanoparticle characterization is vital for mRNA vaccine efficacy, ensuring safety and regulatory compliance in the ...
Biosion, Inc. ("Biosion"), a global clinical-stage biotechnology company, is pleased to announce the appointment of Kedan Lin, Ph.D., as Chief Development Officer and President of Biosion US. With ...
Oregon's bioscience sector has been growing faster than the overall economy, but proposed federal budget cuts could slow its ...
9h
Local News Matters on MSNVacaville welcomes ‘Labyrinthine Heart’ sculpture, a gift from SF’s iconic art projectIn a different kind of heart donation, a Hearts in San Francisco sculpture has been given to the city of Vacaville, city ...
8h
HealthDay on MSNFDA Approves Tablet Form of Evrysdi for Spinal Muscular AtrophyThe U.S. Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for ...
The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with diabetic macular edema (DME) who have previously responded to at least 2 ...
Atomwise, a leader in leveraging machine learning and artificial intelligence (ML/AI) to advance small molecule drug discovery, today announced the appointment of Steve Worland, Ph.D. as Chief ...
The National Institutes of Health has lost two distinguished leaders as mass layoffs directed by the Trump administration hit federal health agencies.
19h
Hosted on MSNBiocurious: Cashed up and pursuing the ‘c’ word, Imugene is on the verge of transforming cancer immunotherapyImugene's trial programs could result in the first 'off the shelf' Car-T therapy that uses healthy donors' cells. ... Read ...
Seasoned Oncology Leader Brings Extensive ADC Expertise to Support Company's New Pipeline MORRISTOWN, N.J., Feb. 18, 2025 /PRNewswire/ -- Aadi Bioscience, Inc.
On-demand video webcast now available here TAMPA, FL / ACCESS Newswire / February 19, 2025 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immune-oncology company dev ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results